Sugi Predict

Sugi Predict / Compounds / SCHEMBL6766348

SCHEMBL6766348

SCHEMBL6766348

COc1cc2nc(O)nc(O)c2c(-c2ccccc2)c1OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC10A2 Q12908 1/20 0.46
▸ PDE4B Q07343 4/20 0.43
▸ PDE4A P27815 3/20 0.43
▸ PDE4C Q08493 3/20 0.43
▸ PDE4D Q08499 3/20 0.43
▸ HSD17B10 Q99714 2/20 0.42
▸ USP2 O75604 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ ALDH1A1 P00352 4/20 0.40
▸ GAA P10253 2/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ HPGD P15428 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ GLA P06280 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ HDAC6 Q9UBN7 1/20 0.40
▸ PDGFRB P09619 1/20 0.40
▸ PDGFRA P16234 1/20 0.40
▸ ADORA2A P29274 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6772470 0.87 SLC10A2 (0.45) SLC10A2PDE4BPDE4APDE4CPDE4D
SCHEMBL7800633 0.87 ADORA2A (0.45) SLC10A2PDE4BPDE4APDE4CPDE4D
SCHEMBL7015217 0.84 PDGFRB (0.46) SLC10A2HSD17B10ALDH1A1GAAALOX15
SCHEMBL3778066 0.80 SLC10A2 (0.56) SLC10A2HSD17B10ALDH1A1GAAALOX15
SCHEMBL11217882 0.79 GAA (0.44) SLC10A2HSD17B10POLBALDH1A1GAA
SCHEMBL6767322 0.76 SLC10A2 (0.46) SLC10A2HSD17B10USP2POLBALDH1A1
SCHEMBL6762248 0.76 MAPT (0.39) SLC10A2HSD17B10POLBALDH1A1GAA
SCHEMBL6762383 0.76 MAPT (0.39) SLC10A2HSD17B10POLBALDH1A1GAA
SCHEMBL6765497 0.74 SLC10A2 (0.45) SLC10A2HSD17B10USP2POLBALDH1A1
SCHEMBL7653476 0.72 SLC10A2 (0.40) SLC10A2PDE4APDE4DHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6750214-B2 PARTICULARLY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA COLLIS ALAN JOHN (US) 2004-06-15 — — US disclosed
US-20030220332-A1 Quinoline and quinazoline compounds useful in therapy PFIZER INC. 2003-11-27 — — US disclosed
US-6642242-B2 Antiproliferative agents to treat benign prostatic hyperplasia PFIZER INC. 2003-11-04 — — US disclosed
US-6103738-A Quinoline and quinazoline compounds useful in therapy PFIZER INC. (US) 2000-08-15 — — US disclosed
EP-0877734-B1 QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY PFIZER RES & DEV (IE) 2000-07-12 — — EP disclosed
CN-1205693-A Quinoline and quinazoline compounds useful in therapy PFIZER RES & DEV (IE) 1999-01-20 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220332-A1 Quinoline and quinazoline compounds useful in therapy NQO2, RFT1, ADRB3 SLC10A2 1147/4885PDE4B 1317/4885PDE4A 1049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.